Through genomic profiling of 259 men with prostate cancer, scientists have identified five groups of prostate cancer with distinct DNA signatures.
Such work is the backbone of President Obama's $215 million precision medicine initiative announced in January, which aims to pioneer a new approach to how we treat disease by moving away from a "one-size-fits-all" approach to medicine to one that takes into account things like a person’s genetic makeup, or the genetic profile of a tumor.
The prostate cancer study, reported in EBioMedicine, used samples from 482 tumors from those men, who were part of studies in Cambridge, Britain, and Stockholm. The scientists identified 100 genes associated with prostate cancer, including 94 that had not been previously associated with the disease.
Most importantly, they found that a small subset of the 100 genes predicted poor prognosis better than any other method that had been used in a clinic setting.
"For the first time in prostate cancer this study demonstrates the importance of integrated genomic analyses incorporating both benign and tumour tissue data in identifying molecular alterations leading to the generation of robust gene sets that are predictive of clinical outcome in independent patient cohorts," the researchers wrote. They said this information could be "used for early detection of aggressive cases in a clinical setting, and inform treatment decisions."